澳门大阳城122.ccapp官方下载

目录产品 » 抗体产品 » 一抗 » SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric
Manual
SDS
COAs
Z03480) .
Coating antigen: recombinant Nucleocapsid Protein, 0.5 µg/ml.
SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (GenScript, A02039) dilution start from 25 µg/ml.
EC50= 0.048 µg/ml. " onclick="clickMainImage(this)" src="/product/documents/down?doc_name=A02039 ELISA.jpg&file=scm_files/productFile_notes/2020/03/27/26ce292c82c2ab90061e8a6b52e9e7af.jpg">

SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric

The product is specific for SARS-CoV-2 Nucleocapsid protein.
￥2800
A02039

产品概述
Specificity The product is specific for SARS-CoV-2 Nucleocapsid protein.
Host Species Human
Immunogen Recombinant SARS-CoV-2 Nucleocapsid Protein
Conjugate Unconjugated
返回

应用指导
Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
Application Recommended Usage
ELISA 0.1-10 µg/ml
返回

产品属性
Form Liquid
Storage Buffer Supplied in PBS, pH 7.4, containing 0.02% sodium azide.
Concentration 1 mg/ml
Storage Instructions Store at -20°C. This product is stable for 1 year upon receipt, when handled and stored as instructed. Avoid repeated freezing and thawing cycles.
Purification Protein A affinity column
Isotype Recombinant human IgG1
Clonality Monoclonal
Clone ID HC2003
Note GenScript can customize this product per customer's request including product size, buffer components, etc.
返回

图例
SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric

ELISA binding of SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (GenScript, A02039) with recombinant Nucleocapsid Protein(GenScript, Z03480) .
Coating antigen: recombinant Nucleocapsid Protein, 0.5 µg/ml.
SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (GenScript, A02039) dilution start from 25 µg/ml.
EC50= 0.048 µg/ml. »

SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric

ELISA binding of SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (GenScript, A02039) with SARS-CoV-2 Nucleocapsid protein (G204R, R203K) (GenScript, Z03731).

Coating antigen: SARS-CoV-2 Nucleocapsid protein (G204R, R203K), 1 µg/ml.

SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric (GenScript, A02039) dilution start from 10 µg/ml.

EC50= 0.105 µg/ml. »

<
>

技术背景
Target Background SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV, is a positive-sense single-stranded RNA virus. It caused coronavirus disease 2019 (COVID-19). Nucleocapsid Protein is a most abundant structure protein of the coronavirus which is associated with nucleic acid.SARS-CoV-2 Nucleocapsid Antibody (HC2003), Human Chimeric is produced from cell culture in vitro under conditions free from animal-derived components.
Synonyms 2019-nCoV Nucleocapsid Antibody (HC2003), SARS-CoV-2 NP Antibody
返回

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


相关文献
Kevin Yau, et al. Omicron variant neutralizing antibodies following BNT162b2 BA4/5 versus mRNA-1273 BA1 bivalent vaccination in patients with end-stage kidney disease. Nat Commun. (2023-09)
Kevin Yau, et al. [Not Available]. CMAJ. (2022-05)
Kevin Yau, et al. Differences in mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 vaccine immunogenicity among patients undergoing dialysis. CMAJ. (2022-02)